- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07897721
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08165784 MONOTHERAPY AND COMBINATIONS IN PARTICIPANTS WITH PIK3CA-MUTATED ADVANCED OR METASTATIC SOLID TUMORS
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment given to stop the growth of cancer. This study also aims to find the best amount of study medication that can be given to patients.
This study is seeking participants with a specific type of breast cancer called hormone receptor-positive (HR+), HER2- negative (HER2-) breast cancer, or colorectal cancer (cancer of the colon or rectum), that has a change (mutation) in a gene called PIK3CA. The cancer must be advanced or metastatic, meaning it has spread to other parts of the body or cannot be completely removed with surgery.
All participants in this study will take the study medication (PF-08165784) as a tablet by mouth. The participant may take the medicine at the study clinic during study visits or at home. Treatment will be given in 28-day cycles and will continue for as long as the participant remains in the study. Depending on which part of the study participants are enrolled into, they will receive the study medication (PF-08165784) alone or in combination with other anti-cancer medications.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Pfizer CT.gov Call Center
- 전화번호: 1-800-718-1021
- 이메일: ClinicalTrials.gov_Inquiries@pfizer.com
연구 장소
-
-
Arkansas
-
Fayetteville, Arkansas, 미국, 72703
- Highlands Oncology Group, PA
-
Rogers, Arkansas, 미국, 72758
- Highlands Oncology Group, PA
-
Springdale, Arkansas, 미국, 72762
- Highlands Oncology Group, PA
-
-
Michigan
-
Grand Rapids, Michigan, 미국, 49546
- START Midwest, LLC
-
-
-
-
-
San Juan, 푸에르토 리코, 00935
- Pan American Center for Oncology Trials, LLC- Hospital Oncológico Office
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 18 years of age or older
- Advanced or metastatic cancer of the breast or colon Part 1A, IB, and 1C: HR+/HER2- advanced or metastatic breast cancer with disease progression after at least 1 line of treatment with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting and received no more than 1 line of prior cytotoxic and/or 1 line of prior ADC therapy in the metastatic setting Part 1D: Metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 2A: HR+/HER2- advanced or metastatic breast cancer with no prior systemic therapy or chemotherapy for advanced or metastatic disease
- PIK3CA mutation
- Archived tumor specimen or fresh tumor biopsy
- Measurable disease
- ECOG performance status 0 or 1
Exclusion Criteria:
- Active or clinically significant dermatologic conditions
- Active malignancy within 3 years prior to enrollment
- Advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term
- Major surgery or radiation therapy within 3 weeks prior to study entry
- Prior irradiation to >25% of the bone marrow
- Active or history of pneumonitis/interstitial lung disease requiring corticosteroids
- Unmanageable ascites
- Prior treatment with PI3K/AKT/mTOR pathway inhibitors may be permitted in certain study cohorts and excluded in others, as specified by the study protocol.
- Renal impairment
- Hepatic dysfunction
- Hematologic abnormalities
- Uncontrolled diabetes
- Cardiac abnormalities
- Active or history of clinically significant GI or inflammatory GI disease
- Other unacceptable abnormalities or prohibited therapies as defined by protocol
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part 1 Dose Escalation Cohort 1A
PF-08165784 monotherapy dose escalation for participants with advanced or metastatic BC at different doses of the study drug |
Taken by mouth (PO) |
|
실험적: Part 1 Dose Escalation Cohort 1B
Combination (PF-08165784 + fulvestrant) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug |
Selective Estrogen Receptor Degrader (SERD)
다른 이름들:
Taken by mouth (PO) |
|
실험적: Part 1 Dose Escalation Cohort 1C
Combination (PF-08165784 + fulvestrant + atirmociclib) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug |
Selective Estrogen Receptor Degrader (SERD)
다른 이름들:
Taken by mouth (PO) Selective CDK4 inhibitor
다른 이름들:
|
|
실험적: Part 1 Dose Escalation Cohort 1D
Combination (PF-08165784 + cetuximab) dose escalation for participants with advanced or metastatic CRC at different doses of the study drug |
Monoclonal antibody (EGFR inhibitor)
다른 이름들:
Taken by mouth (PO) |
|
실험적: Part 2 Dose Optimization/Expansion Cohort 2A
Combination (PF-08165784 + letrozole + atirmociclib) dose optimization/expansion for participants with advanced or metastatic BC, at different doses of the study drug |
Taken by mouth (PO) Selective CDK4 inhibitor
다른 이름들:
Nonsteroidal aromatase inhibitor
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)
기간: Baseline up to 28 days
|
Any adverse events that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes. |
Baseline up to 28 days
|
|
Part 1 (Dose Escalation): Number of participants with laboratory abnormalities
기간: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
Number of participants with laboratory test abnormalities. |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)
기간: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 2 (Dose Expansion): Objective Response Rate (ORR)
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
ORR defined as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 2 (Dose Expansion): Number of participants with laboratory abnormalities
기간: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
Number of participants with laboratory test abnormalities. |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 2 (Dose Expansion): Incidence of Adverse Events (AEs)
기간: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 1 & Part 2: Disease Control Rate (DCR) as per RECIST v1.1
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
DCR is defined as the proportion of participants with CR or PR with confirmation, or Stable Disease (SD) per RECIST version 1.1. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1 & Part 2: Clinical Benefit Rate (CBR) as per RECIST v1.1
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
CBR is defined as the percentage of participants with a best overall response of CR or PR at any time before Progressive Disease (PD), or non-CR/non-PD or SD for at least 24 weeks from start date of treatment and prior to PD, relative to the appropriate analysis set. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1 & Part 2: Duration of Response (DOR) as per RECIST v1.1
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
DOR is defined as the time from first documentation of CR or PR to date of first documentation of PD or death due to any cause. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1 & Part 2: Progression-Free Survival (PFS) as per RECIST v1.1
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1 & Part 2: Time to Response (TTR) as per RECIST v1.1
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
TTR is defined as the time from start date of treatment to first documentation of CR or PR. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 2: Overall Survival (OS)
기간: Up to approximately 2 years
|
OS is defined as time from from start date of treatment to the date of death due to any cause |
Up to approximately 2 years
|
|
Part 1: Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
기간: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
ORR is defined as the percentage of participants in the analysis population having a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST v1.1. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1: Maximum Observed Serum Concentration (Cmax) & Trough Concentration (Ctrough)
기간: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents. |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Time to Reach Maximum Observed Serum Concentration (Tmax)
기간: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents. |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Area Under the Curve (AUC) from Time Zero to Last Quantifiable Concentration (AUClast)
기간: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents. |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Effect of Food on Cmax
기간: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the effect of food on Cmax of PF-08165784 as monotherapy |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Effect of Food on Tmax
기간: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the effect of food on Tmax of PF-08165784 as monotherapy |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Effect of Food on AUClast
기간: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the effect of food on AUClast of PF-08165784 as monotherapy |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 2 (Dose Expansion): Pre- and post-dose concentrations of PF-08165784
기간: Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the pre- and post-dose concentrations of PF-08165784 |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Pfizer CT.gov Call Center, Pfizer
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 부위별 신생물
- 신생물
- 장 질환
- 조직학적 유형에 따른 신생물
- 위장관 신생물
- 소화계 신생물
- 소화기계 질환
- 위장병
- 대장 신생물
- 장 신생물
- 신생물, 선상 및 상피
- 결장 질환
- 피부병
- 유방 질환
- 피부 및 결합 조직 질환
- 암종
- 대장 신생물
- 유방 신생물
- 호르몬
- 호르몬, 호르몬 대체제, 호르몬 길항제
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- Azoles
- 다 환식 화합물
- 항체, 모노클로 날, 인간화
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 스테로이드
- 융합 링 화합물
- 니트릴 레스
- 에스트라 디올
- 에스트 렌스
- Estranes
- 에스트라 디올 선수
- 생식선 스테로이드 호르몬
- 생식선 호르몬
- 트리아 졸
- 레트로졸
- 풀베스트란트
- 세툭시맙
기타 연구 ID 번호
- C6631001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .